论文部分内容阅读
本研究对148例应用头孢哌酮钠舒巴坦钠治疗的患者的临床资料进行分析。从年龄、性别、进食情况、基础疾病、用量及疗程等方面探讨头孢哌酮钠舒巴坦钠致凝血障碍的危险因素,并对凝血障碍组患者予以维生素K治疗,分析其在改善患者PT、APTT方面的作用。结果表明,两组在性别、高血压病、糖尿病及疗程方面无差异(p>0.05),在年龄、肾功能不全、肝病、饮食、给药剂量方面有差异(p<0.05)。治疗后的凝血障碍组患者的PT、APTT均较治疗前降低(p<0.05)。提示年龄、肾功能不全、肝病、饮食、给药剂量是凝血障碍的危险因素,维生素K对机体的凝血障碍有改善作用,值得推广。
In this study, clinical data of 148 patients treated with cefoperazone sodium and sulbactam sodium were analyzed. To explore the risk factors of coagulopathy caused by cefoperazone sodium and sulbactam sodium in terms of age, sex, food intake, basic diseases, dosage and course of treatment, and to treat vitamin C in patients with coagulopathy, and to analyze its effect on improving PT and APTT effect. The results showed that there was no difference in gender, hypertension, diabetes and course of treatment between the two groups (p> 0.05). There were differences in age, renal insufficiency, liver disease, diet and dosage (p <0.05). The PT and APTT of patients with coagulopathy group after treatment were lower than those before treatment (p <0.05). Prompted age, renal insufficiency, liver disease, diet, dosage is a risk factor for coagulopathy, vitamin K on the body to improve the role of coagulation disorders, it is worth promoting.